These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 27123882)
1. Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. van den Brom RR; van Es SC; Leliveld AM; Gietema JA; Hospers GA; de Jong IJ; de Vries EG; Oosting SF Cancer Treat Rev; 2016 May; 46():63-72. PubMed ID: 27123882 [TBL] [Abstract][Full Text] [Related]
2. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma. Chaudhary UB; Hull GW Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795 [TBL] [Abstract][Full Text] [Related]
3. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. Kwan KG; Kapoor A Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804 [TBL] [Abstract][Full Text] [Related]
6. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Biswas S; Kelly J; Eisen T Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692 [TBL] [Abstract][Full Text] [Related]
7. Treatment of elderly patients with metastatic renal cell carcinoma. Zanardi E; Grassi P; Cavo A; Verzoni E; Maggi C; De Braud F; Boccardo F; Procopio G Expert Rev Anticancer Ther; 2016; 16(3):323-34. PubMed ID: 26654225 [TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Godwin JL; Zibelman M; Plimack ER; Geynisman DM Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705 [TBL] [Abstract][Full Text] [Related]
9. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. Raimondi A; Randon G; Sepe P; Claps M; Verzoni E; de Braud F; Procopio G Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480348 [TBL] [Abstract][Full Text] [Related]
15. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma]. Miller K; Bergmann L; Albers P; Jäger E; Jakse G; Geschwend JE; Marschner N Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172 [TBL] [Abstract][Full Text] [Related]
16. Novel immunotherapeutic strategies in development for renal cell carcinoma. Inman BA; Harrison MR; George DJ Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331 [TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623 [TBL] [Abstract][Full Text] [Related]
18. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review]. Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395 [TBL] [Abstract][Full Text] [Related]